Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
hepatitis B
Biotech
Mirum nets Bluejay and its ph. 3-stage hepatitis drug for $620M
Mirum Pharmaceuticals is paying $620 million in cash and stock to buy Bluejay Therapeutics and its phase 3-stage hepatitis drug.
James Waldron
Dec 8, 2025 9:45am
nChroma Bio sheds staff in research reorganization
Nov 12, 2025 5:31pm
Arbutus regains China rights to potential hep B cure from Qilu
Jun 25, 2025 9:15am
Vir won't advance potential hep B 'cure' without a partner
Feb 27, 2025 11:37am
VC firm fights to end Dynavax's 'empire-building' strategy
Feb 19, 2025 2:22pm
2 biotechs shed staff, fuse to form genetic medicine company
Dec 11, 2024 7:00am
